Table of Contents
FORT MILL, S.C. — Lash Group, a patient support services company and a part of AmerisourceBergen, and Medisafe, a leading medication management platform, Tuesday announced that, together, they will provide an end-to-end patient adherence solution that combines a top-rated mobile platform within Lash Group’s current hub services programs.
The Medisafe mobile application provides real-time, personalized interventions using predictive analytics and machine learning, and now through this innovative collaboration, Medisafe will identify “at-risk” patients for Lash Group’s licensed clinicians. This patient journey solution now provides support after therapy is prescribed, but before the first fill. The collaboration also creates visibility into the patient’s approval and shipment status of their medication, while simultaneously providing the opportunity to educate and engage with patients.
“We know that nearly three in four patients are non-adherent to their medication in some way,” said Tommy Bramley, president of Lash Group. “At Lash Group, we are always building on our legacy of helping patients with access, affordability, and adherence to optimize outcomes. We are excited to work with Medisafe to provide an additional layer of digital communication to improve adherence rates and instill healthy behaviors. We meet patient needs by providing both digital and human support to help guide patients on their path to recovery and to a higher quality of life.”
According to the Annals of Internal Medicine, more than 30 percent of initial prescriptions are never filled. And even the 70 percent of patients who do fill a prescription often fall off therapy in the first few months. Medisafe’s research shows that refill rates for its users are as much as 17 percent higher than for non-users.
Specialty medications often require a rigorous health benefit verification and approval process, resulting in long lag times before patients receive their initial supply. Providing patients with transparency into the process and setting expectations on delivery timelines, while assisting with potential copay support program enrollment, can help temper disengagement.
“We are excited to move upstream in the patient journey making it easier for new patients to get started on therapy. And this solution offers patients further support throughout their journey as a trained clinician is never more than a tap away,” said Omri Shor, chief executive officer of Medisafe. “Our strategic collaboration will improve the well-being of patients with severe illness and complex medication regimens at scale by helping them stay adherent to specialty medications for longer. We see great value working with Lash Group to offer this high-tech, high-touch approach.”
